The "cell of origin" of the second most common lung cancer and the way that it becomes dominant in the lung have been ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

A Whangārei retiree funding his own targeted cancer therapy is frustrated that he has to spend more than $25,000 on GST alone ...

Williams, 70, has to pay nearly $180,000 for his cancer therapy, of which more than $25,000 will go on GST. “It’s a tax on ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

The presentations will be accessible via webcast links on the Investor Events section of the Coherus website: Replays of the presentations will be available for 30 days. If you would like to request ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces that the first patient has been enrolled in the Phase 1 clinical trial of its drug candidate 177Lu ...

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

Genelux Corporation’s GNLX share price has dipped by 5.95%, which has investors questioning if this is right time to buy.

WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and ...